The number of health care providers with waivers to prescribe buprenorphine for opioid use disorder increased 19% between October 2021 and September 2022 to 132,005, the Department of Health and Human Services announced today. HHS last April issued revised practice guidelines for administering buprenorphine to treat OUD, which eased requirements for clinicians to obtain a waiver to treat OUD patients with buprenorphine. According to HHS, pharmacy-filled prescriptions for the overdose reversal drug naloxone also increased 37% over the period, from a three-month average of 109,414 prescriptions in October 2021 to 150,213 in August 2022. 
 

Related News Articles

Headline
The AHA Oct. 3 responded to the Medicare Payment Advisory Commission’s recent analysis on the financial impacts of Medicare Advantage enrollment growth on…
Headline
An analysis published Sept. 30 by KFF found that Health Insurance Marketplace enrollees who currently benefit from the enhanced premium tax credits would pay…
Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…
Headline
The AHA Sept. 29 sent recommendations to the Department of Health and Human Services and the Centers for Medicare & Medicaid Services to help ensure…
Perspective
Public
More than 48 million Americans — 16.8% of the 12-and-older population — have a substance use disorder (SUD), according to the 2025 National Survey on Drug Use…
Headline
An AHA blog published Sept. 16 highlights programs and practices by Boston Medical Center leaders and staff that support residents’ mental health, emotional…